Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Co. Ltd.

Division of Samsung Electronics Co. Ltd.
www.samsungbioepis.com

Latest From Samsung Bioepis Co. Ltd.

Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid

Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.

Biosimilars Intellectual Property

Amgen’s Future Looks Brighter After Ruling Lifts Threat Of Enbrel Copycat

Markets are re-assessing Amgen’s long-term value after a US judge upheld two patents relating to Amgen's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis and allowing investors to focus now on the pharma’s promising pipeline.

Commercial Companies

US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Biosimilars Intellectual Property

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.

Australia Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Samsung Electronics Co. Ltd.
  • Senior Management
  • Christopher Hansung Ko, PhD, CEO
  • Contact Info
  • Samsung Bioepis Co. Ltd.
    Phone: 32 455 3114
    107, Cheomdan-daero
    Yeonsu-Gu
    Incheon, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register